Advertising Press Release Distribution |   Reality TV   |  Lifestyle Magazine  |  Kiev Plastic Surgery

Lazer MedSpa News

Everything you need to know about lasers​

Lazer MedSpa News

Month: December 2022

Health

StaffGarden Announces Year-Long Partnership With AdventHealth

StaffGarden Announces Year-Long Partnership With AdventHealthAdventHealth is taking its Nursing Professional Excellence Program digital with StaffGarden’s cloud-based Clinical Ladder Platform Grow

FULLERTON, Calif. – December 12, 2022 – (Newswire.com)

StaffGarden, the leader in software development supporting professional advancement programs such as clinical ladder programs that help nurses advance in their careers, is announcing a year-long partnership with the faith-based healthcare system AdventHealth. AdventHealth has more than 50 hospitals and hundreds of care sites in almost a dozen states, with 6.8 million patient interactions annually.

The clinical ladder is a structured system, traditionally on paper, to support nurses’ career advancement while remaining in their current clinical setting, providing direct patient care.

Digitizing the clinical ladder in healthcare systems to promote nurse engagement has been overlooked in the industry. Grow, from StaffGarden, has stepped in and given nurses a better way to advance their careers by providing software that organizes materials in one centralized hub while tracking engagement. StaffGarden provides innovative technology solutions to over 800 facilities nationwide and will expand further in 2023.

“AdventHealth is an excellent partner to work with,” Brian Card, StaffGarden’s Vice President, said. “It’s truly impressive to see our product impact the healthcare industry, helping nurses progress in their careers and assisting health systems with engagement and retention at such a critical time.”

AdventHealth chose the StaffGarden Grow platform in early 2022 to launch its Professional Excellence Program across the system throughout 2022 and 2023. AdventHealth began with its direct care nurses and later expanded to a second program for assistant nurse managers.

“StaffGarden’s platform has been integral to the successful launch of our national Nursing Professional Excellence Program. It supports the professional development needs of our nursing workforce. The platform is intuitive and makes it easy for our nurses to input the documentation supporting their work,” said Trish Celano, Chief Nurse Executive for AdventHealth. “Also, the review and approval process for our nurse leaders is efficient.” 

About StaffGarden

StaffGarden is the leading digital healthcare company in software development supporting Clinical Ladder, Competency Assessments, Peer Reviews, Magnet Tracking, and Portfolio Management in healthcare systems. StaffGarden is revolutionizing the way nurses track, share and manage their nursing careers. With seven years of experience, we are poised to take your clinical ladder to the next level. To learn more about StaffGarden, check us out on LinkedIn or at StaffGarden.com.

About AdventHealth

With a sacred mission of Extending the Healing Ministry of Christ, AdventHealth is a connected system of care for every stage of life and health. More than 80,000 skilled and compassionate caregivers in physician practices, hospitals, outpatient clinics, skilled nursing facilities, home health agencies, and hospice centers provide individualized, wholistic care. A shared vision, common values, focus on whole-person health, and commitment to making communities healthier unify the system’s more than 50 hospital campuses and hundreds of care sites in diverse markets throughout almost a dozen states. For more information about AdventHealth, visit AdventHealth.com/news.

Contact Information:

Brian Card

VP Sales, Marketing

brian.card@staffgarden.com

(800) 671-3606

Mike Altier

Director, Marketing

mike.altier@staffgarden.com

(800) 671-3606

Press Release Service
by
Newswire.com

Original Source:

StaffGarden Announces Year-Long Partnership With AdventHealth

Read More
Health

Senzo Secures Additional $1.9MM Equity Funding for Its PCR-Accurate Lateral Flow Test

Senzo Secures Additional .9MM Equity Funding for Its PCR-Accurate Lateral Flow TestThe funding, led by existing investors BioAdvance and Wellness Coaches, follows additional 3rd party studies by University College London and LateralDx, confirming that Senzo’s Amplified Lateral Flow (ALF) platform returned greater than 98% accuracy against PCR, including in low viral-load samples

PHILADELPHIA – December 12, 2022 – (Newswire.com)

Senzo, a life sciences company developing high accuracy, low-cost point-of-care diagnostic technologies, today announced a $1.9 million investment led by existing investors BioAdvance and Wellness Coaches.

The funding follows recent blinded studies by UCL and LateralDx, confirming that the Senzo Amplified Lateral Flow test had 98% accuracy in comparison to PCR in correctly identifying COVID-19 virus in samples, even at very low viral loads above 30 Ct. These studies, combined with an earlier study by Sheffield University, demonstrate the high performance of the Senzo Amplified Lateral Flow (ALF) platform. ALF is the only platform that combines the speed and low cost of lateral flow tests with the accuracy of PCR tests.

The investment will be used to complete validation, execute clinical trials, secure FDA EUA authorization, and scale manufacturing for the ALF COVID-19 test, as well as to advance R&D for new Flu A/B, RSV, Tuberculosis, HIV, Hepatitis-C, and Strep tests.

“This funding further indicates the interest and excitement investors have in the ALF platform, and is another important step in bringing our technology to market. Whether for COVID-19, TB, Flu, or a range of other diseases, there are patients in desperate need of better at-home, rapid-test diagnostics, and a huge market needing our tests. This investment will help us bring this innovative technology to market even faster,” said Jeremy Stackawitz, CEO of Senzo Health.

Senzo plans to complete ALF COVID-19 clinical trials and secure FDA EUA regulatory approval in 1H 2023, with tests commercially available in the 2H 2023.

About Senzo:

Senzo is an in vitro diagnostics company developing innovative, accurate, and accessible testing products. Senzo was founded with the vision of utilizing novel technologies, with a focus on enhanced sensitivity, to create mobile, point-of-care and self-testing products and devices with the ability to accurately, quickly, and cost-effectively conduct testing where healthcare professionals and patients need it most. Senzo is creating game-changing products and systems which bring testing to the patient, eliminating the need for the current slow, expensive central-lab testing paradigms.

About BioAdvance:

BioAdvance is an early-stage life sciences fund with a focus in the mid-Atlantic region, investing up to $1.5 million initially and up to $5 million over the lifetime of companies with the potential to significantly improve human health. www.bioadvance.com.

About Wellness Coaches:

Wellness Coaches is one of the largest and most-experienced tech-enabled wellness, nutrition, clinical, and injury prevention service providers, utilizing both onsite and virtual expertise to help communities and organizations increase engagement, improve population health, mitigate safety risks, and reduce healthcare and workers’ compensation costs. www.wcusa.com

For more information, visit https://www.senzo.com.

Press Contact:
Alex Mohacs
alex@senzo.com

Contact Information:

Alex Mohacs

Sales & Marketing

alex@senzo.com

Press Release Service
by
Newswire.com

Original Source:

Senzo Secures Additional $1.9MM Equity Funding for Its PCR-Accurate Lateral Flow Test

Read More
Advertising Business Newspaper |   Miami News   |   Lifestyle Magazine  |   Fashion Magazine | Digital Newspaper Lifestyle Magazine | Woman Magazine Lifestyle News Politic News |   Miami News   |   Lifestyle Magazine |   Politics News   |   Lifestyle Magazine